First Annual University of Chicago Multidisciplinary Breast Cancer Symposium
UChicago Medicine
Antibody Drug Conjugates: Overview and Background of a Revolution in Breast Cancer Treatment
FEATURING
Hope Rugo
- 549 views
- March 4, 2024
- 4
UChicago Medicine
Trastuzumab Deruxtecan in HER2+ mBC
FEATURING
Hope Rugo
- 1,001 views
- March 4, 2024
- 3
UChicago Medicine
2024 Updates on ADCs in HER2-Low, HR+, and TNBC
FEATURING
Hope Rugo
- 210 views
- March 4, 2024
- 3
UChicago Medicine
ADCs in Breast Cancer: Ongoing Trials and Future Directions
FEATURING
Hope Rugo
- 54 views
- March 4, 2024
UChicago Medicine
New and Emerging CDK4/6i Therapies for Advanced HR+ BC
FEATURING
Nan Chen
- 351 views
- March 4, 2024
- 6
UChicago Medicine
Advanced HR+ BC: Elacestrant vs. ET, Alpelisib/Inavolisib for PIK3CAm Tumors, Capivasertib for AKT Pathway-Altered Tumors
FEATURING
Nan Chen
- 244 views
- March 4, 2024
- 1
UChicago Medicine
Advanced ER+ BC: Novel Endocrine Agents Such as ER PROTACs and ER CERANs With Promising Early Phase Data
FEATURING
Nan Chen
- 106 views
- March 4, 2024
- 2
UChicago Medicine
2024 (Neo)Adjuvant Systemic Therapy Updates for HR+ BC
FEATURING
Gini Fleming
- 576 views
- March 1, 2024
- 7
UChicago Medicine
2024 Neoadjuvant IO Updates for HR+ BC
FEATURING
Gini Fleming
- 123 views
- March 1, 2024
- 1
UChicago Medicine
Neoadjuvant & Adjuvant Therapy for HER2+, High-Risk, Early Stage BC
FEATURING
Rita Nanda
- 358 views
- March 1, 2024
- 2
UChicago Medicine
Neoadjuvant & Adjuvant Therapy for High-Risk, Early Stage TNBC
FEATURING
Rita Nanda
- 265 views
- March 1, 2024
- 5
